As demonstrated at the September meeting of the National Task Force on CME Provider/Industry Collaboration, pharmaceutical companies are coming under almost microscopic scrutiny for their activities supporting accredited CME — not only from the Accreditation Council for CME and the Food and Drug Administration, but now also from the Office of Inspector General of the Department of Health and Human Services. OIG is looking for intent to defraud the Medicare and Medicaid programs in every act ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to Printer-friendly, you'll get exclusive access to a large archive of premium content.

Already registered? here.